Subscribe to our Email Alerts


John Lambert PhD GAICD

Chief Executive Officer and Managing Director

John has more than 16 years of drug discovery and development experience. His appointments include leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), as Senior Director (Medicines Development for Global Health) and as an academic researcher in medicinal and biological chemistry (University of Melbourne, ANU and Harvard University).

He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.

John joined Amplia Therapeutics as Operations Manager in August 2018 and was appointed as CEO on 24 June 2019 and Managing Director on 6 February 2020.

Rhiannon Jones BSC (Hons) PhD

Chief Operating Officer

Rhiannon has a background in research operations and project management and more than 10 years of experience in the medical research and biotechnology sector. Rhiannon has previous appointments as Director, Operations and Governance (Cancer Therapeutics CRC), Project Manager (WEHI, Business Development Office), Scientific Coordinator (WEHI, Inflammation Division) and a postdoctoral researcher in organic chemistry (Monash University, Chemistry Department). Her experience includes project management, communications, policy development and oversight, ethics committee submissions, risk management and staff professional development systems.

Rhiannon has a PhD in chemistry and a BSc(Hons) from the University of Adelaide and a Certificate in Governance Practice from the Governance Institute of Australia.

Charlotte Mulder BVSc (Hons), MBA

Principal Development Manager

Charlotte has over ten years’ experience in drug development. Her early career as a Veterinarian in mixed practice in Australia and the UK was followed by a transition into veterinary clinical development with Pfizer Animal Health, then human drug development. Charlotte worked with Medicines Development for Global Health from 2011 until 2021, most recently in the role of Principal Development Manager and Project Leader. She has worked on a variety of projects at different stages of development, spanning preclinical through to regulatory approval. Her experience includes coordination of cross-functional development teams, stakeholder communication, management of international collaborative relationships, and strategic and technical input into development programs.  

Charlotte has a Bachelor of Veterinary Science (Hons) from the University of Melbourne and an MBA from Melbourne Business School.

Anthony Bishop BSc, GradDip

Principal Development Manager

Anthony has more than 25 years of experience in the commercial and operational elements of pharmaceutical development. Beginning at CSL as a production Scientist, Anthony progressed to Project Management Roles. On moving to Singapore, he project managed the first Asian central lab before moving to a business development role at Quintiles (now IQVIA) before leading the development of a new antibiotic through Phase 1 for Merlion Pharma. He helped found a biotech which went on to attract venture capital and moved to Malaysia to run the company. After 16 years in Asia, Anthony returned to Australia into a business development role with Quintiles before leading the development of a biologic for Factor Therapeutics through Phase 2 and then a whole genome diagnostic at genomiQa. His experience covers all aspects of global drug development and commercialisation from both the sponsor and CRO sides of the business.

Anthony has a Bachelor of Applied Science, Medical Laboratory Science from QUT and a Graduate Diploma of Manufacturing Management from RMIT.

Adrian Sulistio B. Eng (Hons), B. Com, PhD.

CMC Project Manager

Adrian has 15 years of experience in early research, process development and GMP manufacture within the life science and biotechnology industries. Prior to joining Amplia, Adrian held a role as Senior Development Scientist at PolyActiva, responsible for developing an ocular drug delivery implant from early-stage research all the way to clinical production. He is a co-inventor on five of patent families. Adrian also held several post-doctoral positions at Monash University and University of Melbourne working in numerous areas in polymer therapeutics, from drug delivery, cancer therapeutics, RNA delivery, antimicrobial polymers, and hydrogels scaffold formation.

Adrian has a Bachelor of Engineering (Chemical, Hons) and Commerce (Finance and Marketing) and a PhD in Polymer Chemistry from University of Melbourne.

Hamish George

Chief Financial Officer

Hamish is a Chartered Accountant and director at Bio101 Financial Advisory Pty Ltd, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector.

Hamish is CFO and/or Company Secretary for numerous ASX listed and unlisted public and private companies. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT and a Certificate in Governance Practice from the Governance Institute of Australia.

Hamish was appointed as Chief Financial Officer of Amplia Therapeutics Limited on 1 October 2021.

Andrew J. Cooke LL.B

Company Secretary

Andrew holds a law degree from Sydney University and has extensive experience in law, corporate finance, governance and compliance. He has over 30 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the biotech, resources, property, mining services and technology sectors focussing on stock exchange, capital raisings, regulatory compliance and a wide range of corporate transactions. 

Andrew was appointed as Company Secretary of Amplia Therapeutics Limited on 11 October 2013.